Obtain a complete understanding of the core pricing competencies utilized by the “Big Four” government agencies in purchasing pharmaceutical and biotechnology products

ACI’s “Big Four” Pharmaceutical Pricing Boot Camp returns once again to bring you an in-depth understanding of the foundations of government pricing as it applies to the “Big 4” agencies. We have recruited the leading voices in relation to “Big Four” pricing concepts and pharmacy benefits programs, including government representatives, leading in-house counsel, and top outside counsel and consultants, who will share their knowledge through presentations and at the multiple networking opportunities.

This in-depth two day training seminar will provide best practices for contracting with “Big Four” agencies and help you:
  • DEVELOP pricing strategies relative to Non-Federal Average Manufacturers Price (non-FAMP) and Federal Ceiling Price (FCP)
  • UNDERSTAND the significance of Acetris Health in light of the applicability of the US Trade Agreements Act to pharmaceutical contracting
  • IMPLEMENT applicability protocols for single and dual pricing models
  • APPRECIATE how the prime vendor and pharmaceutical standardization programs will impact FSS contract holders
  • COMPREHEND the effect of the CMP Final Rule on the 340B program
  • ACHIEVE product placement on the TRICARE formulary

Featuring direct insights from the VA Office of Inspector General, Office of Contract Review:

Marci Anderson Senior Auditor Michael Grivnovics Director, Federal Supply Schedule Division Mark Myers Director, Healthcare Resources Division


“First-time attendee and it exceeded my expectations. The program was very informative and the opportunity to hear from change agents was invaluable.” Prior Delegate
“Comprehensive course. Reinforces current understanding of calculations and obligations under the program while keeping apprised of current issues and considerations” Prior Delegate
“As always the ‘Big Four’ Boot Camp bring together the best in regulatory, legal, and government personnel for an open and honest dialogue.” Prior Delegate
Don’t miss the opportunity to hear from the authority on the key issues in government pharmaceutical contracting today.